Calcium carbonate 250mg tablets

Land: Storbritannien

Sprog: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv bestanddel:

Calcium carbonate

Tilgængelig fra:

Special Order

ATC-kode:

A12AA04

INN (International Name):

Calcium carbonate

Dosering:

250mg

Lægemiddelform:

Oral tablet

Klasse:

No Controlled Drug Status

Recept type:

Valid as a prescribable product

Produkt oversigt:

BNF: 01010201

Indlægsseddel

_S678 LEAFLET Calcichew 20190611 _
PACKAGE LEAFLET: INFORMATION FOR THE USER
CALCICHEW
®
500 MG CHEWABLE TABLETS
(calcium carbonate)
Your medicine is known as Calcichew
®
500mg Chewable Tablets
but will be referred to as Calcichew throughout the following leaflet.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.

Always take this medicine exactly as described in this leaflet or
as your doctor or pharmacist have told you.

Keep this leaflet. You may need to read it again.

Ask your pharmacist if you need more information or advice.

You must talk to a doctor if you do not feel better or if you feel
worse after two weeks.

If you get any side effects talk to your doctor or pharmacist.
This includes any possible side effects not listed in this leaflet.
See section 4.
IN THIS LEAFLET:
1. What Calcichew is and what it is used for
2. What you need to know before you take Calcichew
3. How to take Calcichew
4. Possible side-effects
5. How to store Calcichew
6. Contents of the pack and other information
1. WHAT CALCICHEW IS AND WHAT IT IS USED FOR
Calcichew is orange flavoured chewable tablets containing the
active ingredient calcium. Calcium is found in the diet and is an
important substance in bone formation.
Calcichew is used to treat and prevent calcium deficiency which
may occur if your diet or lifestyle does not provide enough, or when
body requirements are increased. This medicine may also be
prescribed or recommended for certain bone conditions, for
example osteoporosis, or during pregnancy. It may also be given to
patients receiving kidney dialysis to remove the phosphate from the
blood that cannot be removed by dialysis.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE
CALCICHEW
DO NOT TAKE CALCICHEW IF YOU:

are allergic (hypersensitive) to calcium or any of the other
ingredients of this medicine (listed in section 6)

have a condition that causes excessive amounts of calcium in
your blood or urine (hypercalcaemia or hyper

Produktets egenskaber

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Calcium Carbonate / Colecalciferol 1250mg / 400IU chewable tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains
Calcium Carbonate 1250mg (equivalent to Calcium 500mg)
Colecalciferol as Colecalciferol Concentrate (Powder Form) 400 IU
(equivalent to
Vitamin D3 10micrograms).
Excipients with known effect: Aspartame (E951), Sorbitol (E420), and
Sucrose (part
of the Vitamin D3 concentrate: approximately 0.8 milligrams per
tablet).
For the full list of excipients, see Section 6.1
3
PHARMACEUTICAL FORM
Chewable Tablet
White to off white coloured, circular biconvex chewable tablet
debossed with ‘BP’ on
one side and ‘4’ on the other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Tablets should be used only as a therapeutic and not as a food
supplement when the
diet is deficient or when normal requirement of both components is
increased.
Tablets may be used as an adjunct to specific therapy for osteoporosis
or as a
therapeutic supplement in established osteomalacia, pregnant patients
at high risk of
needing such a therapeutic supplementation or malnutrition when
dietary intake is
less than that required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Oral.
Adults and elderly and children over 12 years of age:
Two chewable tablets per day, preferably one tablet each morning and
evening.
Children:
Not recommended for children under 12 years.
4.3
CONTRAINDICATIONS
Absolute contra-indications are hypercalcaemia resulting for example
from myeloma,
bone
metastases
or
other
malignant
bone
disease,
sarcoidosis;
primary
hyperparathyroidism
and
vitamin
D
overdosage.
Severe
renal
failure.
Hypersensitivity to any of the tablet ingredients.
Relative contra-indications are osteoporosis due to prolonged
immobilisation, renal
stones, and severe hypercalciuria.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients
with
mild
to
moderate
renal
failure
or
mild
hypercalciuria
should
be
supervised carefully including periodic checks of pl